Vimta Labs Limited has informed the Exchange regarding a press release dated July 17, 2025, titled "Vimta Labs Limited Reports Q1 FY26 Results".
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts less than Nifty Microcap 250 and 1.5 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vimta Labs reported Q1 FY26 total income of Rs. 993 million, up 31.4% year-on-year from Rs. 756 million in Q1 FY25. EBITDA grew 33.1% YoY to Rs. 354 million with margins expanding to 35.7% (from 35.2% YoY). Profit after tax (from continued operations) rose 35.9% YoY to Rs. 189 million, with PAT margin at 19.0% and basic EPS of Rs. 4.2. For full-year FY25, total income grew 19.1% to Rs. 3,482 million and PAT jumped 36.8% to Rs. 668 million. The Board also approved a 1:1 bonus issue to reward shareholders. The company successfully completed a USFDA GCP inspection with zero observations and received cGMP compliance from ANSM (EMA) during the quarter.
Strong double-digit growth across revenue, EBITDA, and PAT signals robust business momentum post the divestment of the diagnostics business to Thyrocare. The bonus issue and improving margins may be viewed positively by shareholders, though the stock could see short-term adjustment due to the bonus record date mechanics.